The Resistance Equation: Why Prescribing Azithromycin for Viral Infections Is Costing US Communities More Than We Realize

Let's be direct about something the data has been telling us for years: a substantial proportion of azithromycin prescriptions written in the United States each year are clinically unjustified. They are written for patients with viral upper respiratory infections, influenza-like illnesses, and acute bronchitis — conditions in which antibiotics offer no therapeutic benefit whatsoever. And the cumulative consequence of that habit, multiplied across millions of prescriptions annually, is a measurable erosion of azithromycin's effectiveness against the bacterial pathogens it was designed to treat.

This is not a fringe concern or a theoretical future risk. It is happening now, and the evidence is extensive.

The Scale of Inappropriate Prescribing in the US

The Centers for Disease Control and Prevention (CDC) has estimated that at least 28 percent of antibiotic prescriptions in US outpatient settings are unnecessary — a figure that translates to roughly 47 million excess prescriptions per year. Azithromycin consistently ranks among the most frequently prescribed antibiotics in the country, and macrolides as a class account for a disproportionate share of inappropriate outpatient antibiotic use.

Acute respiratory tract infections drive the majority of these prescriptions. Studies published in journals including JAMA and Annals of Internal Medicine have documented that azithromycin is routinely prescribed for acute bronchitis at rates exceeding 70 percent in some US primary care settings — despite the fact that more than 90 percent of acute bronchitis cases are caused by viruses. Similarly, azithromycin is frequently dispensed for upper respiratory infections, sinusitis cases that do not meet bacterial diagnostic criteria, and pharyngitis in patients who test negative for group A streptococcus.

The reasons clinicians reach for the prescription pad in these situations are well-documented: patient pressure and expectation, time constraints during brief office visits, diagnostic uncertainty, and a pervasive cultural narrative that conflates receiving an antibiotic with receiving adequate care. None of these are trivial pressures. But none of them change the microbiology.

What Resistance Actually Looks Like in Clinical Practice

Antibiotic resistance is often discussed in abstract, population-level terms that can feel remote from the exam room. But its clinical consequences are concrete and increasingly visible to US practitioners.

Consider Streptococcus pneumoniae, one of the primary bacterial targets of azithromycin in community-acquired pneumonia. Macrolide resistance rates among pneumococcal isolates in the United States have climbed steadily over the past two decades, with some regional surveillance data reporting resistance rates exceeding 40 percent. When a clinician prescribes azithromycin monotherapy for a patient with genuine bacterial pneumonia in a high-resistance region, the probability of treatment failure is no longer negligible.

The picture is equally troubling for Mycoplasma pneumoniae, historically one of azithromycin's most reliable indications. Reports from Asia initially, and increasingly from US surveillance programs, have documented the emergence of macrolide-resistant Mycoplasma strains. What was once a nearly universally effective treatment for atypical pneumonia is becoming less predictable.

For sexually transmitted infections, the consequences of resistance have already reached a crisis threshold. Neisseria gonorrhoeae has developed such extensive resistance to azithromycin that dual therapy guidelines have been revised, and azithromycin has been removed from CDC-recommended gonorrhea treatment regimens entirely. This is not a warning about a future threat — it is a documentation of a treatment option that has already been lost.

Clinical Scenarios Where Azithromycin Is Prescribed Unnecessarily

To move beyond abstract statistics, it is worth examining specific clinical situations where azithromycin prescribing is common but evidence-unsupported:

Acute bronchitis in otherwise healthy adults. Cough lasting one to three weeks in a non-immunocompromised adult without signs of pneumonia is overwhelmingly viral. Multiple randomized controlled trials have demonstrated that azithromycin provides no meaningful symptom reduction or faster recovery compared to placebo in this population. Appropriate management centers on symptomatic care: adequate hydration, honey for cough suppression (supported by evidence in adults), and patient education about expected illness duration.

Viral sinusitis. The majority of sinusitis presentations in primary care are viral, and even bacterial sinusitis often resolves without antibiotics. Current IDSA guidelines recommend watchful waiting for mild-to-moderate sinusitis symptoms lasting fewer than 10 days. When antibiotic therapy is genuinely indicated, amoxicillin-clavulanate is the preferred first-line agent — not azithromycin.

COVID-19 and influenza. Despite the widespread azithromycin prescribing that occurred during the early COVID-19 pandemic — driven partly by a highly publicized but methodologically flawed French study — multiple large randomized trials, including the RECOVERY trial in the United Kingdom, found no clinical benefit of azithromycin in COVID-19 patients. Prescribing azithromycin for influenza or COVID-19 is not evidence-based and carries all of the resistance consequences without any of the therapeutic benefit.

Strep-negative pharyngitis. Rapid strep tests and throat cultures are widely available and highly reliable. A negative result in a patient with pharyngitis strongly indicates viral etiology. Prescribing azithromycin in this context is both clinically unnecessary and a direct contributor to macrolide resistance in community streptococcal flora.

What Antibiotic Stewardship Programs Have Actually Achieved

The evidence that behavioral and structural interventions can meaningfully reduce inappropriate antibiotic prescribing is now robust. Antibiotic stewardship programs (ASPs), once primarily associated with hospital settings, have demonstrated measurable results in outpatient primary care as well.

A multi-site study conducted across US primary care practices found that a combination of clinician education, patient-facing communication materials, and audit-and-feedback reports reduced inappropriate antibiotic prescribing for acute respiratory infections by more than 20 percent over 18 months. The intervention required no additional technology — only systematic attention to prescribing patterns and structured communication training.

Clinical decision support tools embedded in electronic health record systems have shown similar promise. When EHR systems flag antibiotic prescriptions for viral diagnoses and prompt clinicians to document clinical justification, prescribing rates for inappropriate indications decline — sometimes substantially. The friction introduced by the prompt itself appears to encourage a moment of reflection that the time pressure of a typical office visit otherwise forecloses.

Patient communication is equally critical. Research consistently shows that patients who receive a clear explanation of why an antibiotic will not help their illness — and who are given a specific symptomatic treatment plan — report equivalent satisfaction to patients who receive an antibiotic prescription. The assumption that patients will be dissatisfied without a prescription is, in many cases, a clinician projection rather than a patient preference.

A Call for Honest Prescribing Conversations

Changing the culture of antibiotic prescribing in the United States is not primarily a regulatory challenge. It is a communication challenge. It requires clinicians to be willing to have a slightly longer conversation at the end of a busy clinic day — one that explains what the patient has, why an antibiotic will not help, and what will actually make them feel better faster.

It requires practice administrators and health systems to stop measuring patient satisfaction in ways that inadvertently incentivize unnecessary prescribing. It requires medical education to spend more time on the behavioral dimensions of antibiotic stewardship, not just the pharmacological ones.

And it requires each prescriber to hold in mind a straightforward truth: the azithromycin you write unnecessarily today may be the azithromycin that fails a genuinely sick patient tomorrow. The resistance equation does not balance itself. We balance it, one prescription at a time.